In liver diseases (ALD, non-alcoholic fatty liver disease), AHPN80 inhibits the TLR4/MAPK pathway to reduce liver inflammation and oxidative stress (154), while fucoidan reduces hepatic IL-1β/TNF-α levels to improve metabolic inflammation (257)—showing promise for liver inflammatory disease intervention. This evidence concerns the gene TLR4 and liver disorder.